Home › FDA Grants Priority Review to Mercks Supplemental Biologics License Application (sBLA) Seeking Approval for KEYTRUDA (pembrolizumab) for New Indication in Microsatellite Instability-High Cancer
 

Keywords :   


FDA Grants Priority Review to Mercks Supplemental Biologics License Application (sBLA) Seeking Approval for KEYTRUDA (pembrolizumab) for New Indication in Microsatellite Instability-High Cancer

2016-11-28 13:00:00| Merck.com - Product News

Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) accepted for review the supplemental Biologics License Application (sBLA) for KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, for the treatment of previously treated patients with advanced microsatellite instability-high (MSI-H) cancer. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orKim Hamilton, 908-740-1863orInvestors:Teri Loxam, 908-740-1986orAmy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: review application license approval

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
15.05Tom Hardy Is Jo Malone Londons New Ambassador for Cypress & Grapevine Cologne Intense
15.05Mooncat Introduces New Hue, Holds Bi-Annual Sale
15.05Eastern North Pacific Tropical Weather Outlook
15.05European Wax Center\'s EWC Treat Brightening Ingrown Hair Wipes Awarded
15.05EchoStar pay TV subscribers down 348,000 in 1Q 2024
15.05Atlantic Tropical Weather Outlook
15.05PBE Makes Investment in Plus-Size Adult Incontinence Products
15.05Flint Group retains EcoVadis Silver Medal for 2024
More »